Stockreport

Elevation Oncology to Present Preclinical Proof-of-Concept Data for HER3-ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024 [Yahoo! Finance]

Elevation Oncology, Inc. - Common stock  (ELEV) 
PDF BOSTON March 5, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cance [Read more]